Avantor beats Q1 revenue estimates, reaffirms 2026 guidance

Avantor

29/04/2026 11:16

Overview

U.S. life science tools provider's Q1 sales were flat but beat analyst expectations

Adjusted EPS for Q1 beat analyst expectations

Company reaffirmed full-year 2026 guidance

Outlook

Avantor reaffirms its full-year 2026 financial guidance provided in February 2026

Result Drivers

BIOSCIENCE & MEDTECH EXECUTION - Co said improved execution in Bioscience and Medtech Products contributed to Q1 results

VWR STABILIZATION - Co said it saw stabilization in VWR Distribution & Services segment

REVIVAL INITIATIVE - CEO said Revival initiative is having a positive impact and driving momentum

Company press release: ID:nPn5TxxC4a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Beat
$1.58 bln
$1.54 bln (14 Analysts)
Q1 Adjusted EPS
Beat
$0.17
$0.16 (16 Analysts)
Q1 Net Income
$43.30 mln
Q1 Gross Profit
$500.70 mln
Q1 Operating Income
$99.50 mln
Q1 Pretax Profit
$55.50 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 13 "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Avantor Inc is $10.00, about 27.2% above its April 28 closing price of $7.86

The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 13 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)